A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Assistant Majority Leader Camille Lilly was honored with the American Lung Association in Illinois Impact Award on Wednesday, April 15, for her leadership in advancing tobacco prevention and control, ...

Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...

SAN JUAN, Puerto Rico -- The investigational antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab (Keytruda) ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...

A lower initial lung diffusion capacity for carbon monoxide is associated with a higher rate of progression from very early diagnosis to definite systemic sclerosis.

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.